Top Markets
Coin of the day
Abbott Laboratories Abbott Laboratories

Abbott Laboratories

ABT
Classement en actions #118
Abbott Laboratories, along with its affiliated entities, is a global healthcare... Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Prix de l'action
$97.46
Dernière synchronisation: 2026-10-02
Capitalisation boursière
$168.63B
Changement (1 jour)
0.77%
Changement (1 an)
-27.59%
Pays
US
Échange Abbott Laboratories (ABT)

Catégorie

Ratio P/E pour Abbott Laboratories (ABT)
Ratio P/E au October 2026 TTM : 31.78
Selon les derniers rapports financiers et le cours de l'action de Abbott Laboratories, le ratio P/E actuel (TTM) est de 31.78. À la fin de l’année 2024, le P/E de l’entreprise était de 14.62.
Historique du ratio P/E pour Abbott Laboratories de 2000 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
2026 (TTM) 31.78 -5.28%
2025 33.55 129.56%
2024 14.62 -56.18%
2023 33.35 20.14%
2022 27.76 -21.42%
2021 35.33 -18.19%
2020 43.19 3.69%
2019 41.65 -22.33%
2018 53.63 -74.29%
2017 208.61 416.25%
2016 40.41 170.24%
2015 14.95 -49.70%
2014 29.72 29.04%
2013 23.04 177.98%
2012 8.29 -7.25%
2011 8.93 16.57%
2010 7.66 10.25%
2009 6.95 -13.90%
2008 8.07 -29.75%
2007 11.49 -44.65%
2006 20.76 139.13%
2005 8.68 -19.34%
2004 10.76 -9.48%
2003 11.89 18.37%
2002 10.05 -59.93%
2001 25.07 107.16%
2000 12.10 0.00%
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
21.39 -32.70%
IE
28.32 -10.90%
US
17.60 -44.61%
US
- -
DE
49.61 56.11%
US
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.